The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.

ASP Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$2,260.00
Insider Selling (Last 12 Months): C$0.00

Acerus Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Acerus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acerus Pharmaceuticals Share Price & Price History

Current Price: C$0.36
Price Change: +0.30 (1.20%)
As of 01/26/2023 01:00 AM ET

This chart shows the closing price history over time for ASP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.

Acerus Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2022Edward Joseph GudaitisDirectorBuy500C$4.52C$2,260.0079,482
11/13/2020Borys ChaburskyDirectorBuy400,000C$0.03C$12,000.00457,500
See Full Table
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.

SEC Filings (Institutional Ownership Changes) for Acerus Pharmaceuticals (TSE:ASP)

Acerus Pharmaceuticals logo
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Read More on Acerus Pharmaceuticals

Today's Range

Now: C$0.36
Low: C$0.36
High: C$0.36

50 Day Range

MA: C$0.87
Low: C$0.28
High: C$1.49

52 Week Range

Now: C$0.36
Low: C$0.28
High: C$10.00

Volume

1,300 shs

Average Volume

4,719 shs

Market Capitalization

C$2.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Acerus Pharmaceuticals?

Acerus Pharmaceuticals' top insider shareholders include:
  1. Edward Joseph Gudaitis (Director)
Learn More about top insider investors at Acerus Pharmaceuticals.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.